Serving Biopharma, CROs and R&D companies since 2015
ONCOtracker provides testing services to support your drug and test development needs

IMMUNOASSAY
TEST MENU:
sBCMA: Solubilized B-Cell Maturation Antigen
BAFF: B-Cell Activating Factor
APRIL: A Proliferation Inducing Ligand
Other: Cytokines and Chemokines

Custom assay development and validation available upon request

BIOSPECIMENS
World-class biorepository of clinically characterized specimens from over a thousand multiple myeloma patients. Retrospective, longitudinal, frequently collected specimens with comprehensive clinical data
SPECIMEN TYPES INCLUDE:
◆ Serum ◆ Plasma ◆ Bone Marrow ◆ PBMCs
Prospective collection capabilities available upon request.

PATIENT-DERIVED XENOGRAFTS
Production of five PDX animal models uniquely derived from fresh multiple myeloma human tumor samples from patient’s with diverse backgrounds.

PDX MODELS OFFERING
◆ Complete records on patient’s background and treatment history
◆ Further molecular and characterization studies on the developed tumors
◆ Identification and recording biomarkers predicting treatment response

CONSULTATIVE SERVICES
Our exceptional team of drug discovery and development scientists, clinicians and laboratorians can help address your testing needs.

EXPERIENCED TEAM IN RESEARCH & ASSAY DEVELOPMENT
◆ Study design and protocol writing
◆ Access to clinical sites for obtaining biospecimens
◆ Collaborations with large cancer centers
◆ Assay development specific to myeloma and B-cell diseases
Founded by myeloma research pioneer and oncologist James R. Berenson, M.D., ONCOtracker provides proprietary sBCMA testing, access to an ongoing large library of biospecimens which are longitudinally obtained from patients that are fully characterized, and available for your research needs.

Located in Los Angeles, ONCOtracker's facilities include a state-of-the-art GLP laboratory and biorepository. These are ideally suited to support drug development and clinical studies worldwide with rapid turnaround time of testing results.

ONCOtracker's sBCMA assay is used in pre-clinical and phase I to 3 studies investigating drug therapies for multiple B-cell malignancies. Nearly 20,000 samples have been tested.

sBCMA utility in key areas of investigation:
- Monitor response to therapy
- Predict response to therapy
- BCMA-directed drug development

Please contact us to discuss your drug development needs. Visit our website at www.oncotracker.com or call us at 424.204.0726